Tocilizumab treatment in COVID‐19: A single center experience

Tocilizumab (TCZ), a monoclonal antibody against interleukin‐6 (IL‐6), emerged as an alternative treatment for COVID‐19 patients with a risk of cytokine storms recently. In the present study, we aimed to discuss the treatment response of TCZ therapy in COVID‐19 infected patients. The demographic, tr...

Full description

Saved in:
Bibliographic Details
Published in:J Med Virol
Main Authors: Luo, Pan, Liu, Yi, Qiu, Lin, Liu, Xiulan, Liu, Dong, Li, Juan
Format: Artigo
Language:Inglês
Published: John Wiley and Sons Inc. 2020
Subjects:
Research Articles
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC7262125/
https://ncbi.nlm.nih.gov/pubmed/32253759
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/jmv.25801
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items